Cabaletta Bio (CABA) presented initial dose data from the RESET-PV trial evaluating rese-cel at 1 x 106 cells/kg without preconditioning in three evaluable patients with pemphigus vulgaris. These data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback